NASDAQ: COYA - Coya Therapeutics, Inc.

Rentabilité sur six mois: -2.15%
Secteur: Healthcare

Calendrier des promotions Coya Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis.

plus de détails
The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2022-12-29
ISIN US22407B1089
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.coyatherapeutics.com
Цена ао 8.85
Changement de prix par jour: +8.23% (5.47)
Changement de prix par semaine: +12.98% (5.24)
Changement de prix par mois: -10.98% (6.65)
Changement de prix sur 3 mois: -12.43% (6.76)
Changement de prix sur six mois: -2.15% (6.05)
Changement de prix par an: -20.11% (7.41)
Evolution du prix sur 3 ans: 0% (5.92)
Evolution du prix sur 5 ans: 0% (5.92)
Evolution des prix sur 10 ans: 0% (5.92)
Evolution des prix depuis le début de l'année: -4.98% (6.23)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 12.11 1
P/BV 2.04 7
P/E 0 0
EV/EBITDA -5.46 0
Total: 4.75

Efficacité

Nom Signification Grade
ROA, % -19.35 0
ROE, % -22.41 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -1.77 10
Total: 8.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 1037.17 10
Rentabilité EPS, % 938.19 10
Total: 8
Plus de détails

Établissements Volume Partager, %
Greenlight Capital, Inc. 1274026 8.72
AIGH Capital Management LLC 1031977 7.07
CM Management, LLC 100000 0.68
Vanguard Group Inc 97152 0.67
Worth Venture Partners, LLC 92667 0.63
Geode Capital Management, LLC 92465 0.63
Prelude Capital Management LLC 35770 0.24
Blackrock Inc. 21775 0.15
Potomac Capital Management, Inc. 21101 0.14
Citadel Advisors Llc 16592 0.11

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
iShares Micro-Cap ETF 0.02048 13.79 1.54048



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Howard Berman Ph.D. Chairman & CEO 833.75k 1974 (51 année)
Mr. David S. Snyder CFO & COO 610.94k 1960 (65 années)
Dr. Fred Grossman D.O., FAPA President & Chief Medical Officer 610.63k 1962 (63 année)
Dr. Gregory MacMichael Ph.D. Chief Technical Officer N/A 1956 (69 années)
Dr. Michelle Frazier Ph.D. Senior Vice President of Regulatory Affairs N/A
Mr. Aaron Thome Ph.D. Head of Neuroinflammation Platform N/A
Dr. Arun Swaminathan Ph.D. Chief Business Development Officer N/A

Adresse: United States, Houston. TX, 5850 San Felipe Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.coyatherapeutics.com